C-reactive protein-mediated vascular injury requires complement

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 6, 2010, Pages 1189-1195

  Hage, Fadi G ^a   Oparil, Suzanne ^a   Xing, Dongqi ^a   Chen, Yiu Fai ^a,c   McCrory, Mark A ^b   Szalai, Alexander J ^b  

^a Vascular Biology and Hypertension Program   (United States)

^b The University of Alabama at Birmingham   (United States)

^c BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; C reactive protein; Complement; Vascular biology

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; C REACTIVE PROTEIN; CELL MARKER; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5; MESSENGER RNA;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD VESSEL INJURY; BLOOD VESSEL WALL; CAROTID ARTERY LIGATION; COMPLEMENT ACTIVATION; COMPLEMENT BLOOD LEVEL; COMPLEMENT DEPOSITION; COMPLEMENT SYSTEM; CONTROLLED STUDY; FEMALE; HUMAN VERSUS ANIMAL COMPARISON; IMMUNOFLUORESCENCE TEST; IMMUNOREACTIVITY; IN VITRO STUDY; MACROPHAGE ACTIVATION; MORPHOMETRICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TISSUE DISTRIBUTION; TRANSGENIC MOUSE; UPREGULATION; VASCULAR BIOLOGY;

ANIMALS; ANTIGENS, DIFFERENTIATION; C-REACTIVE PROTEIN; CAROTID ARTERY INJURIES; CAROTID ARTERY, COMMON; CELLS, CULTURED; COMPLEMENT C3; DISEASE MODELS, ANIMAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENOTYPE; HUMANS; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; OLIGONUCLEOTIDES, ANTISENSE; PHENOTYPE; TIME FACTORS; TUNICA INTIMA;

EID: 77952823994     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.205377     Document Type: Article

References (46)

1. Xing D, Hage FG, Chen YF, McCrory MA, Feng W, Skibinski GA, Majid-Hassan E, Oparil S, Szalai AJ. Exaggerated neointima formation in human C-reactive protein transgenic mice is IgG Fc receptor type I (Fc gamma RI)-dependent. Am J Pathol. 2008;172:22-30.
2. Wang D, Oparil S, Chen YF, McCrory MA, Skibinski GA, Feng W, Szalai AJ. Estrogen treatment abrogates neointima formation in human C-reactive protein transgenic mice. Arterioscler Thromb Vasc Biol. 2005; 25:2094-2099.
3. Stein MP, Mold C, Du Clos TW. C-reactive protein binding to murine leukocytes requires Fc gamma receptors. J Immunol. 2000;164: 1514-1520.
4. Lu J, Marnell LL, Marjon KD, Mold C, Du Clos TW, Sun PD. Structural recognition and functional activation of FcgammaR by innate pentraxins. Nature. 2008;456:989-992.
5. Hage FG, McCrory MA, Szalai AJ. C-reactive protein and cardiovascular disease: Lessons learned from studying genetically engineered mice. In: Nagasawa S, ed. C-Reactive Protein-New Research. Hauppauge NY: Nova Publishers; 2008:83-116.
6. Danenberg HD, Szalai AJ, Swaminathan RV, Peng L, Chen Z, Seifert P, Fay WP, Simon DI, Edelman ER. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation. 2003; 108:512-515.
7. Teoh H, Quan A, Lovren F, Wang G, Tirgari S, Szmitko PE, Szalai AJ, Ward ME, Verma S. Impaired endothelial function in C-reactive protein overexpressing mice. Atherosclerosis. 2008;201:318-325.
8. Paul A, Ko KW, Li L, Yechoor V, McCrory MA, Szalai AJ, Chan L. C-reactive protein accelerates the progression of atherosclerosis in apo-lipoprotein E-deficient mice. Circulation. 2004;109:647-655.
9. Hirschfield GM, Gallimore JR, Kahan MC, Hutchinson WL, Sabin CA, Benson GM, Dhillon AP, Tennent GA, Pepys MB. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA. 2005;102:8309-8314.
10. Trion A, de Maat MP, Jukema JW, van der Laarse A, Maas MC, Offerman EH, Havekes LM, Szalai AJ, Princen HM, Emeis JJ. No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-leiden/human C-reactive protein transgenic mice. Arterioscler Thromb Vasc Bio. 2005;25:1635-1640.
11. Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. Clin Immun (Orlando, Fla). 2005;117: 104-111.
12. Lin CS, Xia D, Yun JS, Wagner T, Magnuson T, Mold C, Samols D. Expression of rabbit C-reactive protein in transgenic mice. Immun Cell Bio. 1995;73:521-531.
13. Nakayama S, Mold C, Gewurz H, du Clos TW. Opsonic properties of C-reactive protein in vivo. J Immunol. 1982;128:2435-2438.
14. Torzewski J, Torzewski M, Bowyer DE, Frohlich M, Koenig W, Walt-enberger J, Fitzsimmons C, Hombach V. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol. 1998;18:1386-1392.
15. Oksjoki R, Kovanen PT, Mayranpaa MI, Laine P, Blom AM, Meri S, Pentikainen MO. Complement regulation in human atherosclerotic coronary lesions. Immunohistochemical evidence that C4b-binding protein negatively regulates the classical complement pathway, and that C5b-9 is formed via the alternative complement pathway. Atherosclerosis. 2007;192:40-48.
16. Ciliberto G, Arcone R, Wagner EF, Ruther U. Inducible and tissue-specific expression of human C-reactive protein in transgenic mice. EMBO J. 1987;6:4017-4022.
17. Szalai AJ, van Ginkel FW, Dalrymple SA, Murray R, McGhee JR, Volanakis JE. Testosterone and IL-6 requirements for human C-reactive protein gene expression in transgenic mice. J Immunol. 1998;160: 5294-5299.
18. Bodmer B, Siboo R. Isolation of mouse C-reactive protein from liver and serum. J Immunol. 1977;118:1086-1089.
19. Circolo A, Garnier G, Fukuda W, Wang X, Hidvegi T, Szalai AJ, Briles DE, Volanakis JE, Wetsel RA, Colten HR. Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA. Immunopharmacology. 1999;42: 135-149.
20. Szalai AJ, Hu X, Adams JE, Barnum SR. Complement in experimental autoimmune encephalomyelitis revisited: C3 is required for development of maximal disease. Mol Immunol. 2007;44:3132-3136. (Pubitemid 46610512)
21. Szalai AJ, van Ginkel FW, Wang Y, McGhee JR, Volanakis JE. Complement-dependent acute-phase expression of C-reactive protein and serum amyloid P-component. J Immunol. 2000;165:1030-1035.
22. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1996. (NIH publication 96-01)
23. Tolbert T, Thompson JA, Bouchard P, Oparil S. Estrogen-induced vaso-protection is independent of inducible nitric oxide synthase expression: evidence from the mouse carotid artery ligation model. Circulation. 2001;104:2740-2745.
24. Hage FG, Xing D, Chen YF, Zanardi TA, Graham MJ, Henry SP, Crooke RM, Skibinski GA, McCrory MA, Szalai AJ. Treatment with a human C-reactive protein specific antisense oligonucleotide reduces neointima formation in human C-reactive protein transgenic mice. J Clin Hypertension. 2008;10:A2.
25. Alper CA, Johnson AM, Birtch AG, Moore FD. Human C'3: evidence for the liver as the primary site of synthesis. Science (New York, NY). 1969;163:286-288.
26. Colten HR, Strunk RC, Perlmutter DH, Cole FS. Regulation of complement protein biosynthesis in mononuclear phagocytes. Ciba Found Symp. 1986;118:141-154.
27. Zhou W, Patel H, Li K, Peng Q, Villiers MB, Sacks SH. Macrophages from C3-deficient mice have impaired potency to stimulate alloreactive T cells. Blood. 2006;107:2461-2469.
28. Vlaicu R, Rus HG, Niculescu F, Cristea A. Immunoglobulins and complement components in human aortic atherosclerotic intima. Atherosclerosis. 1985;55:35-50. (Pubitemid 15064937)
29. Reynolds GD, Vance RP. C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. Arch Pathol Lab Med. 1987;111:265-269.
30. Schmiedt W, Kinscherf R, Deigner HP, Kamencic H, Nauen O, Kilo J, Oelert H, Metz J, Bhakdi S. Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol. 1998;18:1790-1795.
31. Thorbjornsdottir P, Kolka R, Gunnarsson E, Bambir SH, Thorgeirsson G, Kotwal GJ, Arason GJ. Vaccinia virus complement control protein diminishes formation of atherosclerotic lesions: complement is centrally involved in atherosclerotic disease. Ann NY Acad Sci. 2005;1056:1-15.
32. Shagdarsuren E, Bidzhekov K, Djalali-Talab Y, Liehn EA, Hristov M, Matthijsen RA, Buurman WA, Zernecke A, Weber C. C1-esterase inhibitor protects against neointima formation after arterial injury in atherosclerosis-prone mice. Circulation. 2008;117:70-78.
33. Patel S, Thelander EM, Hernandez M, Montenegro J, Hassing H, Burton C, Mundt S, Hermanowski-Vosatka A, Wright SD, Chao YS, Detmers PA. ApoE(\/\) mice develop atherosclerosis in the absence of complement component C5. Biochem Biophys Res Commun. 2001;286: 164-170.
34. Buono C, Come CE, Witztum JL, Maguire GF, Connelly PW, Carroll M, Lichtman AH. Influence of C3 deficiency on atherosclerosis. Circulation. 2002;105:3025-3031.
35. Bhatia VK, Yun S, Leung V, Grimsditch DC, Benson GM, Botto MB, Boyle JJ, Haskard DO. Complement C1q reduces early atherosclerosis in low-density lipoprotein receptor-deficient mice. Am J Pathol. 2007;170: 416-426.
36. Mold C, Gewurz H, Du Clos TW. Regulation of complement activation by C-reactive protein. Immunopharmacology. 1999;42:23-30.
37. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111:3481-3488.
38. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. New Engl J Med. 2005;352:1685-1695.
39. Tsimikas S, Willerson JT, Ridker PM. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol. 2006;47:C19-C31.
40. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New Engl J Med. 2008;359:2195-2207.
41. Hage FG, Szalai AJ. C-reactive protein gene polymorphisms, C-reactive protein blood levels, and cardiovascular disease risk. J Am Coll Cardiol. 2007;50:1115-1122.
42. Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, Peden JF, Erdmann J, Braund P, Engert JC, Bennett D, Coin L, Ashby D, Tzoulaki I, Brown IJ, Mt-Isa S, McCarthy MI, Peltonen L, Freimer NB, Farrall M, Ruokonen A, Hamsten A, Lim N, Froguel P, Waterworth DM, Vollen-weider P, Waeber G, Jarvelin MR, Mooser V, Scott J, Hall AS, Schunkert H, Anand SS, Collins R, Samani NJ, Watkins H, Kooner JS. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. J Am Med Assoc. 2009;302:37-48.
43. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. New Engl J Med. 2008;359:1897-1908.
44. Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost. 2009;7(suppl 1):332-339.
45. Marjon KD, Marnell LL, Mold C, Du Clos TW. Macrophages activated by C-reactive protein through Fc gamma RI transfer suppression of immune thrombocytopenia. J Immunol. 2009;182:1397-1403.
46. Colten HR, Garnier G. Regulation of complement protein gene expression. In: Volanakis JE, Frank MM, eds. The Human Complement System in Health and Disease. New York, NY: Marcel Dekker Inc; 1998:217-240.